HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a price target of $33.
September 11, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals (NASDAQ:CRNX) has had its 'Buy' rating reiterated and its price target maintained at $33 by HC Wainwright & Co.
The reiteration of the 'Buy' rating and maintenance of the price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100